192 related articles for article (PubMed ID: 27206953)
41. Tandem hemodialysis and DFPP: Procedure, safety and cost-effectiveness in patients requiring chronic hemodialysis and lipid apheresis.
Moranne O; Chauvel F; Pambrun E; Ahmadpoor P; Prelipcean C; Wuillai A; Chkair S; Messikh Z
J Clin Apher; 2022 Oct; 37(5):476-488. PubMed ID: 36195967
[TBL] [Abstract][Full Text] [Related]
42. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y
Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
[TBL] [Abstract][Full Text] [Related]
43. Prolongation of cardiac xenograft function after reduction of natural antibodies using double filtration plasmapheresis.
Suga H; Ishida H; Kimikawa M; Hayasaka Y; Teraoka S; Agishi T; Ota K
ASAIO Trans; 1991; 37(3):M433-4. PubMed ID: 1751224
[TBL] [Abstract][Full Text] [Related]
44. [Comparison of plasma exchange (PEX) vs. double filtration plasmapheresis (DFPP) with or without steroid administration in a case of MPO-ANCA-positive immune complex type crescentic glomerulonephritis].
Ito C; Ando Y; Akimoto T; Kusano E; Asano Y
Nihon Jinzo Gakkai Shi; 2000 Jul; 42(5):374-80. PubMed ID: 10998918
[TBL] [Abstract][Full Text] [Related]
45. A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis.
Ramunni A; De Robertis F; Brescia P; Saliani MT; Amoruso M; Prontera M; Dimonte E; Trojano M; Coratelli P
Ther Apher Dial; 2008 Jun; 12(3):250-4. PubMed ID: 18503704
[TBL] [Abstract][Full Text] [Related]
46. Optimal Settings for Double Filtration Plasmapheresis With Targeted Removal Rate of Preexisting Antibody in Antibody-Incompatible Kidney Transplant.
Iwami D; Miura M; Chiba Y; Ota M; Matsumoto T; Hotta K; Sasaki H; Hirose T; Harada H; Shinohara N
Transplant Proc; 2018 Dec; 50(10):3478-3482. PubMed ID: 30577224
[TBL] [Abstract][Full Text] [Related]
47. How to improve clotting factors depletion in double-filtration plasmapheresis.
Naciri Bennani H; Marlu R; Terrec F; Motte L; Seyve L; Chevallier E; Malvezzi P; Jouve T; Rostaing L; Noble J
J Clin Apher; 2021 Oct; 36(5):766-774. PubMed ID: 34339059
[TBL] [Abstract][Full Text] [Related]
48. Plasmapheresis for severe lipemia: comparison of serum-lipid clearance rates for the plasma-exchange and double-filtration variants.
Yeh JH; Lee MF; Chiu HC
J Clin Apher; 2003; 18(1):32-6. PubMed ID: 12717791
[TBL] [Abstract][Full Text] [Related]
49. The fluctuation of skin perfusion pressure in hemodialysis patients treated with LDL apheresis therapy: A comparison of LDL adsorption and double filtration plasmapheresis.
Yoshimura H; Yoshikawa Y; Noguchi Y; Totani T; Kusuta R; Shimazu K; Tanaka A; Komura K
J Clin Apher; 2023 Aug; 38(4):362-367. PubMed ID: 36367055
[TBL] [Abstract][Full Text] [Related]
50. Double filtration plasmapheresis in the treatment of hyperproteinemia in dogs affected by
Perondi F; Brovida C; Ceccherini G; Guidi G; Lippi I
J Vet Sci; 2018 May; 19(3):472-476. PubMed ID: 29284208
[TBL] [Abstract][Full Text] [Related]
51. The role of double filtration plasmapheresis in hypertriglyceridemic pancreatitis: A propensity score matching analysis.
Lu Z; Chen Y; Wu Y; Lin Y; Yang N; Wang X; Guo F
J Clin Apher; 2020 Sep; 35(5):388-397. PubMed ID: 32629547
[TBL] [Abstract][Full Text] [Related]
52. Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity.
Hoogerbrugge N; Jansen H; Hoogerbrugge PM
Leukemia; 1997 Aug; 11(8):1377-9. PubMed ID: 9264396
[TBL] [Abstract][Full Text] [Related]
53. [L-asparaginase-induced hyperlipidemia in a case of acute lymphoblastic leukemia].
Konya H; Tamura S; Miyazaki E; Inoue N; Okamoto T; Takemoto Y; Kohsaki M; Kanemaru A; Kakishita E
Rinsho Ketsueki; 1991 Mar; 32(3):250-4. PubMed ID: 2041167
[TBL] [Abstract][Full Text] [Related]
54. Retrospective analysis of long-term lipid apheresis at a single center.
Koziolek MJ; Hennig U; Zapf A; Bramlage C; Grupp C; Armstrong VW; Strutz F; Müller GA
Ther Apher Dial; 2010 Apr; 14(2):143-52. PubMed ID: 20438535
[TBL] [Abstract][Full Text] [Related]
55. Double filtration plasmapheresis: Determination of the optimal albumin concentration in the supplementation fluid.
Mineshima M
Transfus Apher Sci; 2017 Oct; 56(5):654-656. PubMed ID: 28917572
[TBL] [Abstract][Full Text] [Related]
56. Plasmapheresis for hypertriglyceridemia: The association between blood viscosity and triglyceride clearance rate.
Wu HC; Lee LC; Wang WJ
J Clin Lab Anal; 2019 Feb; 33(2):e22688. PubMed ID: 30320483
[TBL] [Abstract][Full Text] [Related]
57. Double filtration plasmapheresis can decrease factor XIII Activity.
Hanafusa N; Kondo Y; Suzuki M; Nakao A; Noiri E; Fujita T
Ther Apher Dial; 2007 Jun; 11(3):165-70. PubMed ID: 17497996
[TBL] [Abstract][Full Text] [Related]
58. Cryofiltration in the treatment of cryoglobulinemia and HLA antibody-incompatible transplantation.
Sinha D; Lambie M; Krishnan N; McSorley K; Hamer R; Lowe D; Briggs D; Fletcher S; Zehnder D; Higgins RM
Ther Apher Dial; 2012 Feb; 16(1):91-6. PubMed ID: 22248202
[TBL] [Abstract][Full Text] [Related]
59. Comparative study of clinical effects between plasma adsorption and double filtration plasmapheresis in patients with myasthenia gravis.
Okada H; Moriwaki K; Sugahara S; Nakamoto H; Hosokawa T; Hamaguchi K; Suzuki H
Ther Apher; 1997 Nov; 1(4):343-7. PubMed ID: 10225728
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic apheresis application using membrane plasma fractionation technology: present scope and limitations.
Sueoka A
Ther Apher; 2000 Jun; 4(3):211-2. PubMed ID: 10910022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
